A
Akm Ghulam Muhammad
Researcher at Cedars-Sinai Medical Center
Publications - 15
Citations - 884
Akm Ghulam Muhammad is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Genetic enhancement & Tumor microenvironment. The author has an hindex of 13, co-authored 15 publications receiving 794 citations. Previous affiliations of Akm Ghulam Muhammad include University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression
Marianela Candolfi,Marianela Candolfi,James F. Curtin,James F. Curtin,W. Stephen Nichols,Akm Ghulam Muhammad,Gwendalyn D. King,Gwendalyn D. King,G. Elizabeth Pluhar,Elizabeth A. McNiel,John R. Ohlfest,Andrew Freese,Peter F Moore,Jonathan Lerner,Jonathan Lerner,Pedro R. Lowenstein,Pedro R. Lowenstein,Maria G. Castro,Maria G. Castro +18 more
TL;DR: The data indicate that murine models of GBM appear to recapitulate several of the human GBM histopathological features and, considering their reproducibility and availability, they constitute a valuable in vivo system for preclinical studies.
Journal ArticleDOI
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics
Marianela Candolfi,Weidong Xiong,Kader Yagiz,Chunyan Liu,Akm Ghulam Muhammad,Mariana Puntel,David Foulad,Ali Zadmehr,Gabrielle E. Ahlzadeh,Kurt M. Kroeger,Matthew Tesarfreund,Sharon Lee,Waldemar Debinski,Dhruv Sareen,Clive N. Svendsen,Ronald Rodriguez,Pedro R. Lowenstein,Maria G. Castro +17 more
TL;DR: A regulatable adenoviral vector encoding a mutated human IL-13 fused to Pseudomonas exotoxin that specifically binds to IL13Rα2 to provide sustained expression, effective anti-GBM cytotoxicity, and minimal neurotoxicity is developed, representing a significant advance in the development of targeted therapeutics for GBM.
Journal ArticleDOI
B Cells Are Critical to T-cell—Mediated Antitumor Immunity Induced by a Combined Immune-Stimulatory/Conditionally Cytotoxic Therapy for Glioblastoma
Marianela Candolfi,James F. Curtin,Kader Yagiz,Hikmat Assi,Mia Wibowo,Gabrielle E. Alzadeh,David Foulad,Akm Ghulam Muhammad,Sofia Salehi,Sofia Salehi,Naomi Keech,Naomi Keech,Mariana Puntel,Chunyan Liu,Nicholas R. Sanderson,Kurt M. Kroeger,Robert Dunn,Gislaine Martins,Pedro R. Lowenstein,Maria G. Castro +19 more
TL;DR: This article showed that modifying the tumor microenvironment through intratumoral administration of adenoviral vectors (Ad) encoding the conditional cytotoxic molecule, i.e., HSV1-TK and the immune-stimulatory cytokine (Flt3L) leads to T-cell-dependent tumor regression in rodent models of glioblastoma.
B Cells Are Critical to T-cell-Mediated Antitumor Immunity Induced by a Combined Immune-Stimulatory/ Conditionally Cytotoxic
Marianela Candolfi,James F. Curtin,Kader Yagiz,Hikmat Assi,Mia Wibowo,Gabrielle E. Alzadeh,David Foulad,Akm Ghulam Muhammad,Sofia Salehi,Naomi Keech,Mariana Puntel,Chunyan Liu,Nicholas R. Sanderson,Kurt M. Kroeger,Robert Dunn,Gislaine Martins,Pedro R. Lowenstein,Maria G. Castro +17 more
TL;DR: The data show that B cells act as APCs, playing a critical role in clonal expansion of tumor antigen-specific T cells and brain tumor regression, in rodent models of glioblastoma.
Journal ArticleDOI
Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.
Marianela Candolfi,Kurt M. Kroeger,Akm Ghulam Muhammad,Kader Yagiz,Catherine Farrokhi,Robert N. Pechnick,Pedro R. Lowenstein,Maria G. Castro +7 more
TL;DR: Examination of currently available animal models for GBM indicates that combination of cytotoxic therapy with immunotherapy will lead to synergistic antitumor efficacy with reduced neurotoxicity and supports the clinical implementation of combined cytot toxic-immunotherapeutic strategies for the treatment of patients with GBM.